We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+2.73%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$7.58B
AUM Growth
+$139M
Cap. Flow
+$177M
Cap. Flow %
2.33%
Top 10 Hldgs %
25.49%
Holding
165
New
14
Increased
52
Reduced
27
Closed
13

Top Buys

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$63.7M
2
FIVN icon
FIVE9
FIVN
+$52.6M
3
XMTR icon
Xometry
XMTR
+$50.4M
4
GLBE icon
Global E Online
GLBE
+$32.3M
5
FVRR icon
Fiverr
FVRR
+$31.6M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$83.1M
2
TRIL
Trillium Therapeutics Inc.
TRIL
+$50M
3
CLDX icon
Celldex Therapeutics
CLDX
+$46M
4
BBIO icon
BridgeBio Pharma
BBIO
+$43.4M
5
RNG icon
RingCentral
RNG
+$39.4M

Sector Composition

Rank Sector Weight
1 Healthcare 34.36%
2 Technology 30.11%
3 Industrials 12.97%
4 Consumer Discretionary 7.19%
5 Communication Services 4.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VCYT icon
76
Veracyte
VCYT
$4.77B
$30.2M 0.4%
651,000
– –
CGNX icon
77
Cognex
CGNX
$10.4B
$28.8M 0.38%
359,000
– –
LII icon
78
Lennox International
LII
$14.5B
$27.9M 0.37%
95,000
– –
DLO icon
79
dLocal
DLO
$4.41B
$27.6M 0.36%
+505,047
New +$28.2M
ROL icon
80
Rollins
ROL
$18.5B
$25.7M 0.34%
727,500
– –
KURA icon
81
Kura Oncology
KURA
$826M
$25.5M 0.34%
1,361,044
+657,044
+93% +$12.4M
COUR icon
82
Coursera
COUR
$1.51B
$25.3M 0.33%
+800,000
New +$30.1M
NVT icon
83
nVent Electric
NVT
$23.4B
$25M 0.33%
772,000
+211,500
+38% +$6.85M
ISRG icon
84
Intuitive Surgical
ISRG
$126B
$24.9M 0.33%
75,000
– –
SWKS icon
85
Skyworks Solutions
SWKS
$9.4B
$24.7M 0.33%
150,047
+2,000
+1% +$366K
MRTX
86
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$22.9M 0.3%
129,471
– –
NBIX icon
87
Neurocrine Biosciences
NBIX
$18.7B
$22.5M 0.3%
235,000
– –
ETNB
88
DELISTED
89bio
ETNB
$22.3M 0.29%
1,137,092
– –
SNDX icon
89
Syndax Pharmaceuticals
SNDX
$1.73B
$22.3M 0.29%
1,165,000
+462,652
+66% +$7.71M
GH icon
90
Guardant Health
GH
$20.2B
$22.3M 0.29%
+178,000
New +$21.1M
MASS icon
91
908 Devices
MASS
$313M
$22.2M 0.29%
682,271
+348,988
+105% +$11.9M
STE icon
92
Steris
STE
$22.5B
$20.7M 0.27%
101,500
+12,800
+14% +$2.74M
TRML
93
DELISTED
Tourmaline Bio
TRML
$20.7M 0.27%
156,109
– –
KLAC icon
94
KLA
KLAC
$236B
$20.5M 0.27%
613,980
+200,000
+48% +$6.68M
MAX icon
95
MediaAlpha
MAX
$732M
$20.5M 0.27%
1,098,246
-92,366
-8% -$2.5M
FIVN icon
96
CALL
FIVE9
FIVN
$2.12B
$19.6M 0.26%
+108,800
New +$19.9M
PHAT icon
97
Phathom Pharmaceuticals
PHAT
$720M
$19.3M 0.25%
600,000
– –
FRC
98
DELISTED
First Republic Bank
FRC
$19M 0.25%
98,600
– –
BFLY icon
99
Butterfly Network
BFLY
$2.14B
$18.5M 0.24%
1,776,000
+411,000
+30% +$4.75M
PLD icon
100
Prologis
PLD
$136B
$18.4M 0.24%
146,500
+8,300
+6% +$1.08M
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q3 2021 Portfolio in Review

As of Q3 2021, Eventide Asset Management held 165 positions worth $7.58B, up 1.9% from $7.44B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Eventide Asset Management's Q3 2021 filing shows 14 new, 52 increased, 27 reduced and 13 closed positions. Its largest new stake was DICE Therapeutics, Inc. Common Stock: 1,871,612 shares worth $59.2M. The largest sale was Biohaven Pharmaceutical Holding Company Ltd., an estimated $83.1M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, down from 36% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q3 2021 buy was DICE Therapeutics, Inc. Common Stock: 1,871,612 shares worth $59.2M.
  • Eventide Asset Management added most to FIVE9 in Q3 2021, an estimated $52.6M increase.
  • Eventide Asset Management's biggest Q3 2021 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $83.1M.
  • Eventide Asset Management fully exited BridgeBio Pharma in Q3 2021, selling an estimated $43.4M.
  • Eventide Asset Management's ten largest holdings make up 25% of its $7.58B portfolio in Q3 2021.
  • Eventide Asset Management opened 14 new positions and closed 13 in Q3 2021.
  • Eventide Asset Management's portfolio value rose 1.9% quarter-over-quarter to $7.58B.

Based on Eventide Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.